Search results with tag "Pegylated liposomal"
AHS Provincial High-alert Medication List
www.albertahealthservices.caliposomal forms of drugs and conventional counterparts (e.g., amphotericin B, amphotericin B-lipid complex, amphotericin B-liposomal, DOXOrubicin HCL, DOXOrubicin-pegylated liposomal, PACLitaxel, PACLitaxel-nab) moderate sedation agents: IV …
DRUG NAME: Doxorubicin pegylated liposomal
www.bccancer.bc.caPegylated liposomal doxorubicin (PLD) is a formulation of doxorubicin in polyethylene glycol (PEG) coated Stealth® liposomes. 3 “Pegylation” is the process whereby the doxorubicin-containing liposomes are enclosed within a PEG layer. 2. Pegylation protects the liposomes
Paclitaxel Protein-Bound (Nab-paclitaxel) (ABRAXANE)
www.pbm.va.govpegylated liposomal doxorubicin Given intravenously every 4 weeks. Risk of cumulative cardiac toxicity. eribulin Given intravenously on days 1 and 8 every 21 days. Primary toxicity includes neutropenia and peripheral neuropathy. ixabepilone Given intravenously every 21 days. May have less activity compared with taxanes, but resulted in less
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euCaelyx pegylated liposomal is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 m g/m² on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euCombination therapy with pegylated liposomal doxorubicin VELCADE 1mg powder for solution for injectionis administered via intravenous injection at the recommended dose of 1.3mg/m2 body surface area twice weekly for two weeks on days1, 4, 8, and 11 in a 21-daytreatment cycle. This 3-week period is considered a treatment cycle. At least 72hours
CANCER DRUG PHARMACOLOGY TABLE
www.bccancer.bc.cadoxorubicin (regular and pegylated liposomal) - epirubicin - idarubicin etoposide mitoxantrone teniposide Hormonal Therapies Antiestrogens oppose the effects of estrogen. tamoxifen – partial estrogen antagonist (antagonist on breast tissue, agonist on endometrium, bone and lipids)
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu2 1. NAME OF THE MEDICINAL PRODUCT Caelyx 2 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of Caelyx contains 2mg doxorubicin hydrochloride in a pegylated liposomal formulation.
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caLast revised: 1 September 2021 2/2 BC CANCER HAZARDOUS DRUG LIST . abemaciclib. 4. DOXOrubicin. 1. olaparib. 4. abiraterone. 1. DOXOrubicin, pegylated liposomal